CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.
Oct 1, 2011
By:
Jim Miller
CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.
|
The EU debt crisis portends of possible negative repercussions for the dose CMO industry.
Sep 1, 2011
By:
Jim Miller
The EU debt crisis portends of possible negative repercussions for the dose CMO industry.
|
Addressing supply-chain challenges.
May 1, 2011
By:
Jim Miller
Addressing supply-chain challenges.
|
Indian manufacturers are not now a threat to Western CMOs, but may be long term.
Mar 1, 2011
By:
Jim Miller
Indian manufacturers are not now a threat to Western CMOs, but may be long term.
|
CDMOs and CMOs face weak economic recovery, consolidation, and globalization.
Jan 1, 2011
By:
Jim Miller
CDMOs and CMOs face weak economic recovery, consolidation, and globalization.
|
Covance's deal with Sanofi-Aventis demonstrates the power of scale and scope.
Dec 1, 2010
By:
Jim Miller
Covance's deal with Sanofi-Aventis demonstrates the power of scale and scope.
|
Venture capital is still scarce for early biotechs and their providers.
Oct 1, 2010
By:
Jim Miller
Venture capital is still scarce for early biotechs and their providers.
|
This month, we catch up on major developments around the world and their implications for the contract services industry.
Aug 1, 2010
By:
Jim Miller
This month, we catch up on major developments around the world and their implications for the contract services industry.
|
How much to spend on early development, whether to use your CMO's proprietary cell line, and other outsourcing advice.
Jul 1, 2010
By:
Jim Miller, Susan Dana Jones
How much to spend on early development, whether to use your CMO's proprietary cell line, and other outsourcing advice.
|
|
